Minimal impact of selective susceptibility reporting on the use of piperacillin-tazobactam for Escherichia coli and Klebsiella bacteremia.

Abstract	Selective cascade reporting of antibiotic susceptibilities did not have a significant impact on de-escalation from piperacillin-tazobactam (PT), duration of PT use, length of stay, or rates of acute kidney injury and Clostridioides difficile infection in patients with positive monomicrobial blood cultures with either Escherichia coli or Klebsiella spp.
Authors	Yorgo Zahlanie, Brenton C Hall, Wenjing Wei, Norman S Mang, Jessica K Ortwine, Shelby Anderson, Kristi Morgan, Tamara P Guzman, Linda S Hynan, Bonnie C Prokesch
Journal	Infection control and hospital epidemiology (Infect Control Hosp Epidemiol) Vol. 42 Issue 10 Pg. 1272-1274 (10 2021) ISSN: 1559-6834 [Electronic] United States
PMID	33423705 (Publication Type: Journal Article)
Chemical References	Anti-Bacterial Agents Piperacillin, Tazobactam Drug Combination
Topics	Anti-Bacterial Agents (therapeutic use) Bacteremia (drug therapy) Escherichia coli Humans Klebsiella Piperacillin, Tazobactam Drug Combination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!